On 7 June, the FDA approved aducanumab, the first new drug for Alzheimer’s disease in almost 20 years—and notably, the first drug with a putative disease‐modifying mechanism for the treatment of this devastating disorder, namely the removal of β‐amyloid (or Aβ) plaques from the brain
Development of disease-modifying treatments for Alzheimer\u27s disease (AD) has been challenging, wi...
Alzheimer’s disease (AD) is the most common cause of dementia, and its rising prevalence is constant...
As our collective biomedical knowledge increases, we find ourselves increasingly reliant on the expe...
The US FDA approved Aducanumab in June 2021 as the first Alzheimer's disease (AD) drug under its acc...
Alzheimer's disease is the most common form of dementia, affecting millions of people, including fam...
Alzheimer’s disease (AD) is the most common form of dementia affecting millions of individuals, incl...
Alzheimer’s disease (AD) is the main cause of disability in people older than 60 years. More than 1 ...
Alzheimer’s disease (AD) is a neurodegenerative disorder affecting millions of people around the wor...
Aducanumab, co-developed by Eisai (Japan) and Biogen (U.S.), has received Food and Drug Administrati...
Alzheimer’s disease (AD) is the most common cause for dementia worldwide. Until recently, all approv...
Alzheimer's disease (AD) is characterized by deposition of amyloid-β (Aβ) plaques and neurofibrillar...
DeclarationsFunding The preparation of this review was not supported by any external funding.Authors...
International audienceResearch on disease-modifying treatments for Alzheimer's disease has resulted ...
Alzheimer’s disease (AD) is an irreversible, progressive brain disorder that slowly destroys the mem...
In October 2019, the American pharmaceutical company Biogen stated intention to apply to the US Food...
Development of disease-modifying treatments for Alzheimer\u27s disease (AD) has been challenging, wi...
Alzheimer’s disease (AD) is the most common cause of dementia, and its rising prevalence is constant...
As our collective biomedical knowledge increases, we find ourselves increasingly reliant on the expe...
The US FDA approved Aducanumab in June 2021 as the first Alzheimer's disease (AD) drug under its acc...
Alzheimer's disease is the most common form of dementia, affecting millions of people, including fam...
Alzheimer’s disease (AD) is the most common form of dementia affecting millions of individuals, incl...
Alzheimer’s disease (AD) is the main cause of disability in people older than 60 years. More than 1 ...
Alzheimer’s disease (AD) is a neurodegenerative disorder affecting millions of people around the wor...
Aducanumab, co-developed by Eisai (Japan) and Biogen (U.S.), has received Food and Drug Administrati...
Alzheimer’s disease (AD) is the most common cause for dementia worldwide. Until recently, all approv...
Alzheimer's disease (AD) is characterized by deposition of amyloid-β (Aβ) plaques and neurofibrillar...
DeclarationsFunding The preparation of this review was not supported by any external funding.Authors...
International audienceResearch on disease-modifying treatments for Alzheimer's disease has resulted ...
Alzheimer’s disease (AD) is an irreversible, progressive brain disorder that slowly destroys the mem...
In October 2019, the American pharmaceutical company Biogen stated intention to apply to the US Food...
Development of disease-modifying treatments for Alzheimer\u27s disease (AD) has been challenging, wi...
Alzheimer’s disease (AD) is the most common cause of dementia, and its rising prevalence is constant...
As our collective biomedical knowledge increases, we find ourselves increasingly reliant on the expe...
DOI
Add to ORKG